The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The deals cover Plexbio's IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the IVD and life science research markets.
The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.
The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
Under the partnership, DNAnexus customers will have direct access to the Dragen Genome Pipeline for "ultra-rapid" genome analysis.
The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.